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Abstract
The evidence for believing that mixtures of aspirin, phenacetin, and caffeine provide advantages over the individual components of these mixtures is reviewed, and doubt expressed as to the rationale for the use of these mixtures in ordinary medical practice. The syndrome of 'analgesic nephropathy' is also reviewed, and on the basis of experiments in healthy volunteers it is suggested that individual ingredients of analgesic mixtures be scrutinized more carefully in an attempt to track down the agents responsible for toxic effects.
The use of phenothiazine compounds, alone or in mixture with narcotics, is reviewed, and the opinion expressed that methotrimeprazine has special analgesic attributes.
The narcotic antagonists represent an extremely interesting group of drugs which possess analgesic activity as well as the ability to antagonize certain effects of morphine and other narcotic agents. The patterns of respiratory effect, psychotomimesis, and abstinence phenomena seen with these antagonists illustrate the possibility of dissociating certain effects usually assumed to be linked inseparably in drugs possessing the analgesic power of morphine. This discussion will be limited to three major areas: (1) Certain analgesics commonly taken by mouth.
(2) Phenothiazine tranquilizers as analgesic agents. (3) Narcotic antagonists and 'narcotic antagonist-analgesics'.
Drugs of the aspirin-phenacetinl-caffeine (APC) class are widely used by the lay public and often prescribed by physicians. One might well ask: Why are these mixtures so popular? Why were they first proposed? If the introduction of APC mixtures can be attributed to a rational approach at either the animal or clinical level, the historical evidence has escaped me. It is more likely (Smith 1958 ) that the APC tablet was a result of the polypharmacy so prevalent in the last century. Phenacetin (acetophenetidin) seems to have been introduced, like aspirin, as an antipyretic drug, and perhaps as a euphoriant, rather than as an analgesic. With the passage of time, reports began to appear of its use as an analgesic, particularly in cases of headache, migraine, and neuralgia. The use of caffeine as a stimulant is well known and pharmacologically acceptable, but its use in the management of headaches is in a large part based on anecdotal reports, rather than on modern scientific trials. pound well known to produce ulcerative lesions in the gastric mucosa, raises the possibility of a potentiation of gastric toxicity. In this connexion, it is of interest that in certain reported series of cases of the so-caRed 'nephropathy of analgesic abuse', there has been a high incidence of gastrointestinal bleeding or ulceration, frequently of a recurrent nature. Prescott (1965) in our group has accumulated some most interesting data in regard to the urinary sediment in volunteers given the doses of drug shown in Table 1 . It would appear from his results (Table 2) that the effects of APC tablets on renal tubular cell excretion are less dramatic than those of aspirin, although there has not yet been an opportunity to study multiple dose levels of In more recent decades, one finds the use of APC tablets justified on the basis either of increased efficiency in relieving certain types of pain, or decreased toxicity from the giving of 'half-doses' of the individual ingredients aspirin and phenacetin. What is the evidence to support these allegations ?
The curves in Fig I are typical of our experience in controfled trials with APC mixtures. In this particular experiment, which involved patients with postpartum pain, each given a different popular proprietary remedy, there is a clearcut difference between the various aspirin and APC preparations as a group, and placebo, but there are only unimpressive differences between the several active treatments (DeKornfeld et al. 1962 ). Patients given repeated doses of these preparations in another aspect of this trial, on the other hand, did report somewhat greater gastrointestinal irritation from the two APC preparations'. Anacin and especially Excedrin, which also contained salicylamide, so that any slight advantage of increased analgesia seemed to be offset by increased gastrointestinal toxicity. Other trials have yielded similar results: either a suggestion that APC tablets are slightly better than aspirin, or no difference at all (Cass & Frederik 1962) . There is adequate pharmacological reason to expect certain kinds of additional side-effects from APC tablets, as compared with aspirin, since caffeine itself can lead to mental ov.-Irstimulation; and the combination of caffeine, a stimulant to gastric secretion, and aspirin, a com- individual drugs. Acetaminophen (paracetemol) alone, presumably the major metabolite of phenacetin, interestingly enough seems so far relatively benign in terms of renal irritation, although it is unquestionably an effective analgesic ( Fig 2) . Furthermore, two subjects who have shown a brisk rise in tubular cell excretion on phenacetin have shown no abnormalities on equal doses of acetaminophen.
Before leaving this topic, it might be well to consider that the popularity of mixtures of this general type may be related less to analgesia than to effects on mood. In a study of nurses suffering from dysmenorrhea, we found 20 % of our experimental population enthusiastic for the treatments that contained, as one ingredient, 5 mg of amphetamine per dose. It seems reasonable to suspect that in the management of something like dysmenorrhea or recurrent headache, where mood disturbances so frequently accompany pain, the presence of drugs of the amphetamine-caffeine variety may provide therapeutic benefit which is not reflected in pain ratings.
Phenothiazines are important drugs in the management of certain neuropsychiatric conditions, but their place in the treatment of pain is Keats et al. (1961) have reported a beautifully designed study comparing promethazine with placebo, pethidine, and a mixture of promethazine and pethidine. Their data show no analgesic effect from promethazine and, by comparison with placebo, no potentiation by promethazine of the analgesic performance of pethidine. Our experience with another phenothiazine, Triflupromazine, is shown in Fig 3. The addition of 5 or 10 mg of this phenothiazine to 50 mg of pethidine (meperidine) did not alter the analgesic performance of the latter. We have been impressed, on the other hand, by the performance of methotrimeprazine, whose formula is shown in Fig 4. This phenothiazine is a useful tranquilizer and is perhaps as powerful a sedative as any in this class. Fig 5 illustrates our results with this compound in the management of labor pain (DeKornfeld et al. 1964) . We have had similar experience with the drug in the management of post-operative pain (Lasagna & DeKornfeld 1961) . There seems little reason to doubt that methotrimeprazine is a powerful analgesic compound, and that the pain relief it provides is not merely consequent on a severe and general dulling of the senses. We have not studied the combination of methotrimeprazine with morphine or pethidine, but (Tables 3 and 4 ). Methotrimeprazine does appear to have a depressant effect on respiration when volunteers are breathing room air, although the combination of full doses of methotrimeprazine and morphine did not produce an alarming degree of respiratory depression. When volunteers were breathing 6 % carbon dioxide, however, there appeared to be no depression ofrespiration from methotrimeprazine, suggesting that the depression seen when the volunteers were breathing room air was due to general sedation rather than to specific depression of the respiratory center. The combination of the two drugs seemed again to give results not very different from those seen with morphine alone.
Finally, some words about narcotic antagonists. Our attention was directed to these compounds as a result of some studies done a dozen years ago in a naive attempt to find a combination of narcotic antagonist and narcotic analgesic that (Lasagna & Beecher 1954) . Respiratory depression was seen with the narcotic antagonist alone and with the narcotic antagonist combined with narcotic analgesic. Accidentally, however, we discovered during these studies that nalorphine itself was a powerful analgesic agent. Since then Dr Arthur Keats and his colleagues, as well as our own group, have searched among narcotic antagonists for possible substitutes for morphine. is capable of equalling the analgesic performance of 10 mg of morphine if given in doses of approximately 40 mg. It appears to have little propensity for addiction of the morphine type, although it is a respiratory depressant. As in the case of nalorphine and other narcotic antagonists, however, this respiratory depression appears to reach a plateau at a level below the peak effects seen with narcotics. If the maximal respiratory depression is considerably lower with these antagonists than with a drug like morphine or pethidine, this should provide an increased margin of safety in man. In some limited experiments by Keats and his colleagues, they have been unable to antagonize the respiratory depression of pentazocine by the use of other narcotic antagonists. They have, however, been able to reverse the depression with a stimulant such as methylphenidate (Ritalin). respiratory depressant effect levels off. A dose of 0 25 mg cyclazocine seems similar to 10 mg of morphine in respiratory depressant effect. However, on quadrupling this dose, there is no further increase in respiratory depressant effect, such as one would expect with morphine. Fig 12 shows the analgesic performance of cyclorphan, a morphinan derivative with the same cyclopropylmethyl side chain (on the nitrogen group) that is present in cyclazocine. This compound is perhaps an even more powerful analgesic than cyclazocine, on a milligram basis. There is a strange biphasic quality to the response with this antagonist, with 1 mg of naloxone appearing inferior to 2 mg of naloxone as an analgesic, but with higher doses of naloxone also looking less impressive than 2 mg, and perhaps even hyperalgesic or 'anti-analgesic', since the performance of 8 mg is worse than one might have expected from a placebo. Naloxone does not appear to have psychotomimetic properties, whereas the other powerful narcotic antagonists I have mentioned, cyclazocine, cyclorphan, and nalorphine, have. Pentazocine, which is a weak narcotic antagonist, apparently has this psychotomimetic capacity only to a minor degree, although one group of investigators has observed a reasonably high incidence of bizarre subjective effects in patients receiving the drug by mouth in doses which have appeared benign when given parenterally by other investigators.
It is fascinating that at least two of these antagonists, nalorphine and cyclazocine, appear to be capable of producing physical dependence. The abstinence syndromes on withdrawal of these drugs are clear-cut, although not morphine-like. The post-addicts who have served as experimental subjects in these experiments seem to have little or no desire for the effects produced by these drugs, so that their liability for abuse by potential addicts seems slight.
These compounds, whatever their ultimate role in medicine, have illustrated the possibility of dissociating certain effects which have often been assumed in the past to be linked inseparably in analgesics possessing the power of morphine. The patterns of respiratory effect, psychotomimesis, and abstinence phenomena seen after these antagonists indicate important differences between the antagonists and related nonantagonist analgesic drugs. 
The complex mechanisms that maintain the blood pressure can be interfered with at many points by drugs. A drug acting at one point may be potentiated by another which blocks a compensatory reflex minimizing the effect of the first. Many therapeutically useful drug combinations have a nonspecific mechanism of this kind although drugs that act upon different points in the sympathetic efferent vasomotor pathway have not been proved to have a useful additive effect.
It is not easy to prove a synergistic action of two drugs unless it is large. The best supported examples are combinations of either a diuretic or a vasodilator with a sympathetic blocking drug. These combinations are the ones most widely used in treatment of hypertension. They allow the dose of each active substance to be reduced so that unwanted side-effects are decreased without losing the desired action on the blood pressure.
Drug combinations have special risks besides their obvious advantages. Patients are more likely to become confused and take the wrong doses if their treatment regime is complicated. Two drugs which are individually nontoxic may have dangers when used together. Oliguria and a mounting blood urea may follow combined use of powerful modern diuretics. Toxic effects may be entirely unrelated to the main therapeutic action of the drug, as with the enhanced diabetogenic effect of diazoxide used with hydrochlorothiazide.
Several potent cardiovascular drugs modify the response to drugs which might be given to raise the blood pressure in an emergency. No drug in common therapeutic use seriously reduces the response to injected noradrenaline but some, such as sympathetic blockers and monoamine oxidase inhibitors, greatly increase sensitivity. Pressor amines that act indirectly by noradrenaline release may be ineffective in the presence of drugs which deplete or insulate the stores of the transmitter in adrenergic nerve endings.
The advantages and disadvantages of drug interactions deserve more thought and study than they usually receive.
Polypharmacy is a word used in a derogatory sense to describe the simultaneous use of a number of drugs without a rational pharmacological basis. In many ways this is a fair description of present practice in the treatment of hypertension, for it is by no means unusual for three or four different drugs to be administered in combination. The reason for this policy is the difficulty of controlling blood pressure and the relatively high incidence of side-effects exhibited by most drugs used to treat hypertension.
